Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 5Phase 1 3Phase 2/3 2Phase 3 1

Status

Active not recruiting 3Recruiting 2Completed 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Gemcitabine 12Dexamethasone 12Magnetic Resonance Spectroscopy 10Bevacizumab 10venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Docetaxel 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7130-nm albumin-bound paclitaxel 7Methotrexate 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Ramucirumab × Clear all
NCT06203600 2026-05-26

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
224 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT06616584 2026-05-05

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Recruiting
378 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡